drugset / Trial / NCT07330674
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
Timeline
- Start
- 2026-02
- Primary completion
- 2027-11
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABF-101 | Unknown | — | Oral |